INSIGHTS ON CONTRACT PHARMA MANUFACTURING

• Straight From The Source: A Live Q&A With The Inventors Of KinetiSol™

  Experts discuss a solvent-free fusion process for amorphous solid dispersions, highlighting formulation flexibility, scale-up, process control, and early strategies to reduce risk and support commercialization.

• Why Emerging Drug Developers Can't Afford To Delay Analytical Development

  Rushing early pharma development by neglecting quality and analytical frameworks risks regulatory failures, clinical holds, and expensive rework.

• Where Formulation Expertise Connects

  As pipelines grow more complex and timelines become more ambitious, companies increasingly rely on strong external partners to advance their drug products efficiently and with reduced risk. 

• Strategic CDMO Partnerships Begin By Unraveling The Complexities

  Selecting the right CDMO is critical for pharmaceutical sponsors. To avoid pitfalls, sponsors should evaluate a CDMO's capacity, technical capabilities, quality metrics (like CAPA effectiveness and deviation times), financial stability, and talent retention. Establishing strong communication, supply chain transparency, and routine quality audits also helps ensure a successful, long-term partnership.

• WuXia TrueSite

  Targeted integration adds predictability to cell line development by cutting clone screening, improving expression consistency, and accelerating timelines to ease early CMC bottlenecks.

• Safeguarding Biologic Quality And Performance

  A science‑driven roadmap, from QTPP to QbD and phase‑appropriate strategies, helps ensure biologics stability, manufacturability, and a smooth path to successful commercialization

• Enhancing Biologics Developability With Predictive In Silico Modelling

  Predictive in silico modeling accelerates biologics development by identifying stability and formulation risks early, enabling smarter candidate selection, reduced costs, and improved success rates.

• Flamma: From Yesterday To Today 2022

  A fast look at how decades of scientific ambition, strategic growth, and quality focus shaped a trusted partner—connecting past decisions to today’s life‑science collaborations.

• Sterile Filtration Of Budesonide As A Preferred Sterilization Strategy

  Accelerate development of high‑quality inhalation therapies by leveraging sterile‑filtered budesonide to safeguard purity, stability, and patient safety.

• A Blueprint For Clinical-Grade Gene Therapy Production

  View a scalable, open-access AAV9 manufacturing process improving yield, purity, and consistency through optimized transfection and downstream purification for clinical-grade gene therapy production.